CN Patent

CN113784716A — 药物组合物

Assigned to True Tumor Technology Co ltd · Expires 2021-12-10 · 4y expired

What this patent protects

本发明涉及用于治疗或预防与内分泌紊乱相关的症状(比如潮热)的药物组合物。所述药物组合物包含含三环氨基的式(I)化合物，比如MSX‑122(也称为“Q‑122”)(N,N'‑(1,4‑亚苯基双(亚甲基))双(嘧啶‑2‑胺))，以及一种或多种药学上可接受的赋形剂。所述药物组合物可以按一定剂量和/或给药方案提供，优选每天两次。

USPTO Abstract

本发明涉及用于治疗或预防与内分泌紊乱相关的症状(比如潮热)的药物组合物。所述药物组合物包含含三环氨基的式(I)化合物，比如MSX‑122(也称为“Q‑122”)(N,N'‑(1,4‑亚苯基双(亚甲基))双(嘧啶‑2‑胺))，以及一种或多种药学上可接受的赋形剂。所述药物组合物可以按一定剂量和/或给药方案提供，优选每天两次。

Drugs covered by this patent

minocycline-hydrochloride (MINOCYCLINE HYDROCHLORIDE)

Patent Metadata

Patent number: CN113784716A
Jurisdiction: CN
Classification: —
Expires: 2021-12-10
Drug substance claim: No
Drug product claim: No
Assignee: True Tumor Technology Co ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.